company background image
KNTE

Kinnate Biopharma NasdaqGS:KNTE Stock Report

Last Price

US$7.61

Market Cap

US$336.1m

7D

-4.6%

1Y

-61.9%

Updated

29 Nov, 2022

Data

Company Financials +
KNTE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

KNTE Stock Overview

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States.

Kinnate Biopharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kinnate Biopharma
Historical stock prices
Current Share PriceUS$7.61
52 Week HighUS$21.68
52 Week LowUS$5.75
Beta0
1 Month Change-12.63%
3 Month Change-47.45%
1 Year Change-61.91%
3 Year Changen/a
5 Year Changen/a
Change since IPO-80.50%

Recent News & Updates

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Sep 21

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Sep 15
Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Recent updates

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Sep 15
Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

May 15
We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Jan 24
Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Oct 09
We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Jun 22
Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Mar 03
We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Shareholder Returns

KNTEUS BiotechsUS Market
7D-4.6%-1.0%-0.9%
1Y-61.9%-15.2%-18.9%

Return vs Industry: KNTE underperformed the US Biotechs industry which returned -16.1% over the past year.

Return vs Market: KNTE underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is KNTE's price volatile compared to industry and market?
KNTE volatility
KNTE Average Weekly Movement12.1%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: KNTE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: KNTE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201886Nima Farzanhttps://www.kinnate.com

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Kinnate Biopharma Inc. Fundamentals Summary

How do Kinnate Biopharma's earnings and revenue compare to its market cap?
KNTE fundamental statistics
Market CapUS$336.09m
Earnings (TTM)-US$110.87m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KNTE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$110.87m
Earnings-US$110.87m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.51
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did KNTE perform over the long term?

See historical performance and comparison